title: Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
abstract: BACKGROUND
  Daily monitoring of peripheral blood CD34+ cells may not be necessary for all patients with hematologic malignancies for adequate peripheral blood progenitor cells (PBPC) mobilization and harvesting. We therefore designed a regimen for PBPC mobilization in patients with multiple myeloma or pre-treated Non-Hodgkin's lymphoma based on a combination of low-dose cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) without daily monitoring of peripheral blood CD34+ cells.
  
  
  METHODS
  A prospective study was performed on patients with multiple myeloma (n = 22) or pre-treated Non-Hodgkin's lymphoma (n = 17) whose PBPC were harvested according to the following regimen: 1.5 g/m(2) Cy at day 1, 12 microg/kg/day G-CSF from day +7 to +11 avoiding daily monitoring of peripheral blood CD34+ cells and two consecutive leukapheresis at days +12 and +13. The optimum threshold of 2x10(6) CD34+ cells per kg was established.
  
  
  RESULTS
  The proportion of patients with higher CD34+ cell yield after two leukapheresis was similar: multiple myeloma (16/22-72.7%) and Non-Hodgkin's lymphoma (12/17-70.6%). Exposure to radiotherapy and greater than two prior chemotherapy regimens were significantly associated with lower yield in multiple myeloma (p = 0.002) and Non-Hodgkin's lymphoma patients (p = 0.002), respectively.
  
  
  CONCLUSIONS
  Our data suggested that adequate yields of CD34+ cells may be achieved in multiple myeloma or pre-treated Non-Hodgkin's lymphoma mobilized with low-dose Cy plus G-CSF regardless of the daily monitoring of peripheral blood CD34+ cells.
authors.affiliation: Serviço de Hematologia e Hemoterapia de São José dos Campos, São José Dos Campos, São Paulo 12210-040, Brazil. fcallera@vivax.com.br
authors.forename: Fernando
authors.initials: F
authors.lastname: Callera
authors.forename: Luciana
authors.initials: L
authors.lastname: Cavenaghi
authors.forename: Cláudio M T P
authors.initials: CM
authors.lastname: de Melo
mesh_terms: D000293:Adolescent; D000328:Adult; D053687:Adult Stem Cells / Q000187:drug effects*; D000368:Aged; D018791:CD4 Lymphocyte Count; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011446:Prospective Studies; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide